Edition:
United Kingdom

Novelion Therapeutics Inc (NVLN.OQ)

NVLN.OQ on NASDAQ Stock Exchange Global Select Market

3.31USD
24 Sep 2018
Change (% chg)

$-0.23 (-6.50%)
Prev Close
$3.54
Open
$3.54
Day's High
$3.54
Day's Low
$3.31
Volume
18,005
Avg. Vol
23,068
52-wk High
$7.27
52-wk Low
$2.97

Latest Key Developments (Source: Significant Developments)

Novelion Therapeutics Reports Qtrly Net Loss Per Common Share-$1.67
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Novelion Therapeutics Inc ::NOVELION THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 REVENUE $31.9 MILLION VERSUS $40.9 MILLION.QTRLY NET LOSS PER COMMON SHARE-BASIC AND DILUTED $1.67.QTRLY LOSS PER SHARE $1.67.  Full Article

Novelion Therapeutics Reports Quarterly Net Loss Per Share Of $1.76
Thursday, 10 May 2018 

May 10 (Reuters) - Novelion Therapeutics Inc ::NOVELION THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 REVENUE $27.5 MILLION VERSUS $30 MILLION.QUARTERLY NET LOSS PER SHARE $1.76.  Full Article

Novelion Therapeutics Announces Cost Reduction Plans, Capital Structure Review
Wednesday, 24 Jan 2018 

Jan 24 (Reuters) - Novelion Therapeutics Inc ::NOVELION THERAPEUTICS ANNOUNCES COST REDUCTION PLANS AND CAPITAL STRUCTURE REVIEW.NOVELION THERAPEUTICS -ANNOUNCED COST REDUCTION PLANS AS IT MANAGES CASH RESOURCES, EFFECTS OF DELAY & UNCERTAINTY OF SETTLEMENT OF UNIT WITH DOJ, SEC.NOVELION THERAPEUTICS - IN ADDITION TO WORKFORCE AND OTHER COST REDUCTIONS, PURSUING LICENSING OPPORTUNITIES FOR ITS ZURETINOL DRUG CANDIDATE.  Full Article

Edgepoint Investment Group Reports 10.6 Pct Passive Stake In Novelion Therapeutics
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Novelion Therapeutics Inc ::EDGEPOINT INVESTMENT GROUP INC REPORTS 10.6 PERCENT PASSIVE STAKE IN NOVELION THERAPEUTICS INC AS OF NOVEMBER 30 - SEC FILING.  Full Article

Novelion Therapeutics Appoints Michael Price As CFO
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Novelion Therapeutics Inc ::NOVELION THERAPEUTICS APPOINTS MICHAEL PRICE AS SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER.NOVELION THERAPEUTICS INC - ‍GREGORY PERRY HAS RESIGNED AS CFO TO PURSUE OTHER OPPORTUNITIES, AND WILL REMAIN WITH COMPANY UNTIL DECEMBER 31, 2017​.NOVELION THERAPEUTICS INC - ‍APPOINTS MICHAEL PRICE AS SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, EFFECTIVE DECEMBER 4, 2017​.  Full Article

Novelion Therapeutics provides update on agreement between Aegerion Pharma and U.S. Department of Justice
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Novelion Therapeutics Inc :Novelion Therapeutics provides update on agreement between Aegerion Pharmaceuticals and U.S. Department of Justice.Novelion Therapeutics - ‍district judge William Young rejected Aegerion Pharmaceuticals' amended criminal plea agreement which was negotiated with U.S. DOJ.Novelion Therapeutics Inc - ‍company, in consultation with its outside counsel, is currently evaluating its options and next steps​.  Full Article

Novelion Therapeutics says CEO resigns, posts Q3 results
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Novelion Therapeutics Inc :Novelion Therapeutics reports third quarter 2017 financial results and announces leadership change.Sees FY 2017 revenue $135 million to $145 million.Q3 revenue $28.7 million.Novelion Therapeutics Inc - ‍Company reiterates FY 2017 guidance for total net revenues of $135-$145 million​.Novelion Therapeutics Inc - ‍Chief Executive Officer Mary Szela has resigned for personal reasons, effective immediately​.Novelion Therapeutics Inc - ‍Board announced creation of an interim office of chief executive officer​.Qtrly loss per share $2.67 ‍​.Novelion Therapeutics Inc - ‍Continues to anticipate EMA approval for Metreleptin​ in first half of 2018.  Full Article

Morgan Stanley reports 5.2 pct passive stake in Novelion Therapeutics
Friday, 22 Sep 2017 

Sept 22 (Reuters) - Morgan Stanley :Morgan Stanley reports 5.2 percent passive stake in Novelion Therapeutics Inc as of Sept 12, 2017 - SEC filing.  Full Article

Qlt reports Q3 loss per share $0.11
Tuesday, 1 Nov 2016 

Qlt Inc - : Says operating loss for Q3 of 2016 was $6.0 million, compared to $2.8 million for same period in 2015 . Says net loss per common share was $0.11 in Q3 of 2016, . Says continues its phase III pivotal trial start-up activities to test safety and efficacy of its drug product, qlt091001 . Says is currently exploring potential of submitting to fda a request for a rare pediatric disease designation of qlt091001. . Qlt announces third quarter 2016 results .Q3 loss per share $0.11.  Full Article

Former Aegerion sales rep charged with defrauding U.S. insurers

NEW YORK, May 15 A former Aegerion Pharmaceuticals Inc sales representative was arrested Tuesday on charges that he defrauded insurance companies into paying for the company's expensive cholesterol drug.